Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Body Dysmorphic Disorder

  • Author: Iqbal Ahmed, MBBS, FRCPsych(UK); Chief Editor: David Bienenfeld, MD  more...
 
Updated: Mar 23, 2016
 

Practice Essentials

The essential feature of body dysmorphic disorder (BDD) is preoccupation with an imagined defect in appearance or disproportionate concern with a slight physical anomaly. By definition, BDD causes significant distress or impairment in important areas of functioning.

Signs and symptoms

Common areas of perceived imperfections in BDD include the following:

  • Skin
  • Face
  • Nose
  • Mouth
  • Hair
  • Eyelids
  • Wrinkles
  • Excessive greasiness
  • Acne
  • Excessive facial hair
  • Nasal size and shape
  • Teeth
  • Bite of jaw
  • Breasts
  • Genitals
  • Buttocks
  • Lips

The clinical picture typically illustrates many of the following behaviors:

  • Ritualistic behaviors aimed at confirming the “defect” or avoiding its recognition by others
  • Need for constant reassurance from others
  • Expenditure of considerable time (1 hour or more, sometimes as much as 8 hours) daily on thoughts and behaviors relating to the “defect”
  • Repeated seeking of dermatologic or cosmetic referral for correction of the “defect”

Asking the following 4 questions may be helpful:

  1. Are you worried about how you look? (Yes/No); if you are, do you think about your appearance problems a lot and wish you could think about them less? (Yes/No)
  2. How much time per day, on average, do you spend thinking about how you look? - (a) Less than 1 hour a day; (b) 1-3 hours a day; (c) more than 3 hours a day
  3. Is your main concern with how you look that you aren’t thin enough or that you might become too fat? (Yes/No)
  4. How has this problem with how you look affected your life? - (a) Has it often upset you a lot? (Yes/No); (b) has it often gotten in the way of doing things with friends, your family, or dating? (Yes/No); (c) has it caused you any problems with school or work? (Yes/No); (d) are there things you avoid because of how you look? (Yes/No)

Patients are likely to have BDD if they give the following answers:

  • Question 1 - Answer of “yes” to both parts of the question
  • Question 2 - Answer of (b) or (c)
  • Question 3 - Whereas an answer of “yes” answer may indicate that BDD is present, it is possible that an eating disorder is a more accurate diagnosis
  • Question 4 - Answer of “yes” to any of the 4 parts of the question

See Presentation for more detail.

Diagnosis

No specific laboratory tests or imaging studies are indicated for suspected BDD. Screening questionnaires may be helpful. A mental status examination should be carried out and may include the following findings:

  • Mood - Depressed mood, as well as irritability and anxiousness
  • Thought process - Perseveration on physical appearance, particularly in association with the perceived defect
  • Thought content - Thoughts about the perceived defect that may be so divorced from reality as to become delusional; suicidal and homicidal ideation may be present

Except for the amount of time and energy spent on the preoccupation, findings from the mental status examination are usually within normal limits.

See Workup for more detail.

Management

Medications that may be employed in treating BDD include the following:

  • Selective serotonin reuptake inhibitors (SSRIs; eg, fluoxetine, fluvoxamine, escitalopram, and citalopram) - These agents are generally preferred
  • Tricyclic antidepressants (TCAs; in particular, clomipramine)
  • Neuroleptics (eg, pimozide)
  • Trazodone
  • Lithium
  • Benzodiazepines
  • Monoamine oxidase inhibitors (MAOIs) - These should be given only if all other modalities fail and probably should be prescribed only by experienced specialists

Psychotherapy (especially CBT) and behavioral modification therapy are highly recommended in addition to treatment with SSRIs. Approaches include the following:

  • Systematic desensitization
  • Exposure techniques
  • Self-confrontational techniques
  • Cognitive imagery

General strategies are as follows:

  • Consistent treatment, generally by the same physician
  • Supportive office visits scheduled at regular intervals
  • Gradual shifting of focus from symptoms to personal and social problems
  • Efforts to prevent body inspection rituals and reassurance seeking [1, 2]

Surgical considerations include the following:

  • Given that more than 90% of BDD patients report symptoms that are unchanged and often exacerbated after surgical procedures, plastic or cosmetic surgery intended to correct the perceived defect in BDD is contraindicated
  • In all suspected cases of BDD, any proposed surgical treatment must be thoroughly documented and discussed with patients

See Treatment and Medication for more detail.

Next

Background

Body dysmorphic disorder (BDD)—formerly referred to as dysmorphophobia, dysmorphic syndrome, dermatologic hypochondriasis, or dermatologic nondisease in various contexts—is a relatively common and often severe psychiatric illness that is likely underrecognized and underreported.[3, 4, 5, 6, 7] It is classified in the category of obsessive-compulsive and related disorders in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).[8] If left untreated, BDD can become a chronic condition.

The essential feature of BDD is a preoccupation with an imagined defect in appearance or disproportionate concern with a slight physical anomaly. These preoccupations most often involve the nose, the ears, the face, hair, or features related to sexuality (eg, breasts in women or muscular build or penis size in men); however, any body part may occupy the patient’s focus.

Social values and mass media greatly influence body image and, in turn, self-image. Most people have concerns related to appearance; however, this concern is considered pathologic when it interferes with social or occupational functioning. By definition, BDD causes significant distress or impairment in these areas.[9]

BDD usually appears during early adolescence. Parents of children with BDD may seek psychiatric evaluation after witnessing excessive mirror checking, time-consuming grooming, and an inability to be reassured about the perceived flaw. From a developmental perspective, some preoccupation with appearance is common during adolescence; the hallmark of BDD in adolescents is, as noted, clinically significant distress or impairment in functioning.

A key characteristic of BDD is that patients seek actions, such as cosmetic surgery, to correct their perceived malformation. Patients whose symptoms are exclusively focused on a preoccupation with body weight and shape or perceived inappropriateness of sexual characteristics are not diagnosed with BDD and frequently meet criteria for other disorders, such as anorexia nervosa or gender identity disorder.

Data suggest that quality of life and psychosocial functioning are at least as poor in patients with BDD as in those with obsessive-compulsive disorder (OCD).[10] BDD is associated with high rates of hospitalization (48%), as well as high rates of suicidal ideation and attempts.[11, 12] A history of suicidal ideation attributed primarily to BDD is reported in 45-70% of those with BDD, and past suicide attempts are reported in 22-24%.[13]

BDD affects 2.4% of the general population and reportedly affects as many as 7-15% of those undergoing cosmetic surgery.[8, 14, 15, 16] Persons with BDD who choose to undergo plastic surgery are generally unhappy with the results and often subsequently become concerned with another body part. They are often consumed by thoughts about the postoperative site. Surgeons and dermatologists have occasionally been victims of violence, even murder, by BDD patients who are in despair over their procedural outcomes.[17]

Diagnostic criteria (DSM-5)

Specific DSM-5 criteria for BDD are as follows[8] :

  • The individual is preoccupied with 1 or more perceived defects or flaws in physical appearance that are not observable by or appear slight to others
  • At some point during the course of the disorder, the individual has performed repetitive behaviors (eg, mirror checking, excessive grooming, skin picking, or reassurance seeking) or mental acts (eg, comparing his or her appearance with that of others) in response to the appearance concerns
  • The preoccupation causes clinically significant distress or impairment in social, occupational, or other important areas of functioning
  • The appearance preoccupation cannot be better explained by concerns with body fat or weight in an individual whose symptoms meet diagnostic criteria for an eating disorder

The diagnosis may also specify whether muscle dysmorphia is present. In such cases, individuals are preoccupied with the idea that their physical build is too small or not muscular enough. This specifier is used even if individuals are also preoccupied with other body areas.

In addition, the diagnosis may specify patients’ level of insight into their BDD beliefs as follows:

  • Good or fair insight - The individual recognizes that the BDD beliefs are definitely or probably untrue, or at least that they may or may not be true
  • Poor insight - The individual feels that the BDD beliefs are probably true
  • Absent insight or delusional beliefs - The individual is completely convinced that the BDD beliefs are true
Previous
Next

Pathophysiology

At present, the pathophysiology of BDD is understood to only a highly limited extent; however, it remains a subject of continuing research.[18] Studies have highlighted a variety of plausible mechanisms, including such hypotheses as abnormal visual processing and hypo−N-methyl-D-aspartate (NMDA) receptor (NMDAR) signal transduction.[19, 20] A more robust understanding of BDD’s pathophysiology will surely inform and improve available treatment options.

Patterns of heritability have been noted. Family members of patients diagnosed with BDD show a prevalence rate of BDD that is 4-8 times that found in the general population. There is also a heritable association with BDD in patients with OCD. Accordingly, genetic factors are suspected of playing a role in the pathogenesis of BDD.[21] Unfortunately, the studies that could more fully illuminate the molecular genetic basis of BDD have yet to be done.[22]

A 2000 study by Deckersbach et al found that patients with BDD had impaired verbal and nonverbal memory encoding strategies.[23] This finding suggests an involvement of executive memory deficits with a lesion of the frontostriatal connections. A similar abnormality in memory encoding also occurs in patients with OCD. Additionally, enlarged white matter volume and asymmetry of the caudate nucleus, favoring the left side, have been observed in patients with BDD.

A 2007 study by Feusner et al found that BDD may be associated with fundamental differences in visual processing of faces.[22] The study also found that subjects with BDD had greater left hemisphere activation and might have a cognitive style that relies more on extraction and processing of details. The authors suggested that BDD patients may process faces in a piecemeal manner, whereas healthy controls’ perception of faces may be more configural and holistic.

Several studies have explored the possible role of disrupted serotonergic transmission in the development of BDD. Many of these are based on evidence that illustrates the effectiveness of selective serotonin reuptake inhibitors (SSRIs) in the treatment of BDD. Overall, the exact role for serotonergic transmission in the etiology of BDD remains the subject of continuing research.[22, 24]

In addition to the neuroanatomic, neurochemical, and genetic models for explaining BDD, several cognitive-behavioral models have been developed. It is recognized that most people are unsatisfied with at least 1 aspect of their appearance; the signal characteristic of people with BDD is that they are obsessed with any such perceived defects.

Individuals with BDD are believed to use maladaptive cognitive processes that overemphasize the importance of perceived attractiveness.[25, 26] By this logic, their disproportionate emphasis on physical attractiveness leads them to view themselves negatively, so that they experience low self-esteem, anxiety, shame, and sadness, commonly reporting to maladaptive coping methods such as mirror-gazing or avoidance.[27]

Previous
Next

Etiology

At present, the causes of BDD have not been established, though numerous theories have been advanced.

Heredity may contribute to the development of this condition. The prevalence of BDD is 4 times higher in first-degree relatives of BDD patients than in relatives of probands without the disorder. BDD appears to be related to OCD, in that it occurs frequently in OCD patients and their relatives and responds to the same medications.[28, 29, 30, 31]

Brain anomalies may be important causes. Functional abnormalities in visual processing, frontostriatal, and limbic systems have been documented. Diffusion-weighted magnetic resonance imaging (MRI) of white matter suggested a relation between impaired insight (a clinically important phenotype) and fiber disorganization in tracts connecting visual with emotion/memory processing systems.[32]

Another study found disturbances in whole-brain structural topologic organization in subjects with BDD.[33] The authors also found evidence of abnormal connectivity between regions involved in lower-order visual processing and those involved in higher-order visual and emotional processing, as well as interhemispheric visual information transfer, which may relate to abnormalities in information processing.

A study investigating the potential role of early-life sexual, physical, or emotional abuse in the development of BDD found that subjects with BDD had more retrospective experiences of sexual and physical abuse during childhood or adolescence than healthy control subjects did.[34] Such findings suggest that abuse might be a potential risk factor in the development of BDD.

Previous
Next

Epidemiology

United States statistics

Because of frequent comorbidity with other conditions, the diagnosis of BDD is often overlooked. BDD is estimated to affect 1-2% of the general US population.[35, 36] Given that the condition is underdiagnosed, this may be an underestimate. Patients underreport to their physicians because of intense shame. The prevalence of BDD appears to be significantly higher among people receiving dermatologic care—as high as 11.9% in one study.[37]

The prevalence of BDD in patients undergoing plastic or cosmetic surgery ranges from 7% to 15%.[16] Patients who undergo cosmetic surgery do not seem to have increased incidence of generalized body dissatisfaction; however, when surveyed about specific body parts, they have a much higher incidence of specific body part dissatisfaction.[38]

International statistics

The international incidence and prevalence of BDD have not been determined with any precision or accuracy.

BDD is a relatively common disorder among individuals seeking aesthetic surgery in Iran, being seen in about a quarter of those seeking rhinoplasty.[39] In São Paulo, Brazil, the prevalence of BDD in dermatologic patients was evaluated in a sample of 150 patients in a cosmetic group, 150 patients in a general dermatology group, and 50 control subjects; the prevalence in the cosmetic group was 14%, compared with 6.7% for the general group and 2% for the control group.[40]

Age-related demographics

The onset of BDD typically occurs in adolescence or young adulthood (average age of onset, 16-17 years[41] ). The condition may also occur in older adults who are overly concerned with their aging appearance. The course of BDD is usually continuous over time, with waxing and waning symptoms. For many patients, BDD becomes chronic. The body part that is the focus of concern may remain the same or may change over time.

Sex-related demographics

BDD affects men and women with nearly equal frequency; female-to male ratios are in the range of 1:1 to 3:2.[42] In terms of most clinical features, male and female BDD patients appear to be more similar than different,[8] though males and females tend to focus on different types of perceived defects.[43, 11]

Women more often have comorbid anxiety and panic disorder and are obsessed with legs and breasts; they are also more likely to have a comorbid eating disorder. Men, particularly those who engage in weightlifting or body building, are more likely to become preoccupied with their muscle size (so-called muscle dysmorphia).[44] Men are also more likely to have genital preoccupations, to have a diagnosis of substance abuse (50% of cases), and to be single.

Race-related demographics

No data are available on the relationship between BDD and race. However, cultural values and preferences may influence symptom content to some degree. Taijin kyofusho, a syndrome included in the traditional Japanese diagnostic system, has a subtype resembling BDD.[8]

Previous
Next

Prognosis

BDD results in significant suffering, occupational dysfunction, or social malaise. Many patients affected by BDD have comorbid conditions such as OCD, major depression, delusions, or social phobia.

If fully and appropriately treated with both pharmacotherapy and psychotherapy, BDD generally has a good prognosis. A small prospective study of the course of BDD found the probability of full recovery to be relatively high (0.76) and the probability of recurrence after remission to be low (0.14 over 8 years).[45] The presence of a delusional intensity of belief or comorbid conditions may necessitate more extensive and intensive therapy and follow-up.

Of those with a primary diagnosis of BDD, 30% also meet the criteria for OCD. The 2 conditions have many features in common, including repetitive thoughts concerning a perceived defect and activities centered on concealing or confirming the perceived deformity that consume most of the patient’s time. Compared with OCD, BDD has much higher rates of poor insight, ideas of reference, overvalued ideas, and delusions.

Major depression is a common comorbidity, occurring in some 60% of patients with BDD; these patients also are at increased risk for suicide.[46, 47] Suicidal ideation attributed primarily to BDD is reported in 45-70% of those with BDD, and past suicide attempts are reported in 22-24%.[13] Preliminary data from a pilot study suggest that the annual rate of completed suicide in BDD may be unexpectedly high (at 0.3%).[13]

Individuals with BDD have variable degrees of awareness concerning the psychiatric nature of the illness. Many continue to agonize about an imagined defect even when they are cognizant that their concerns are excessive. Other people with BDD are regarded as delusional and have no insight into their unusual behavioral tendencies.

In many cases, individuals with BDD experience drastic social and occupational dysfunctions that may progress to the point of social isolation. Psychosocial functioning tends to remain poor over time, with few attaining functional remission.[48, 49]

In one study, BDD was evident in almost 50% of subjects with an eating disorder.[50] Accordingly, efforts should be made to recognize BDD in patients with eating disorders, especially because the presence of this disorder will affect treatment.

Previous
Next

Patient Education

In both cognitive-behavioral psychotherapy and behavioral modification, patient education is an important component of care; education of family members is also valuable. For patient education resources, see the Depression Center, as well as Anorexia Nervosa and Depression.

A helpful online resource for patients is BDD Central. Helpful online resources for family education include the following:

Previous
 
 
Contributor Information and Disclosures
Author

Iqbal Ahmed, MBBS, FRCPsych(UK) Faculty, Department of Psychiatry, Tripler Army Medical Center; Clinical Professor of Psychiatry, Uniformed Services University of the Health Sciences; Clinical Professor of Psychiatry, Clinical Professor of Geriatric Medicine, University of Hawaii, John A Burns School of Medicine

Iqbal Ahmed, MBBS, FRCPsych(UK) is a member of the following medical societies: Academy of Psychosomatic Medicine, American Neuropsychiatric Association, American Society of Clinical Psychopharmacology, Royal College of Psychiatrists, American Association for Geriatric Psychiatry, American Psychiatric Association

Disclosure: Nothing to disclose.

Coauthor(s)

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, New York Academy of Medicine, American Academy of Dermatology, American College of Physicians, Sigma Xi

Disclosure: Nothing to disclose.

Lawrence Genen, MD, MBA Board Certified Psychiatrist; Diplomate, American Board of Psychiatry and Neurology; Founder, The Genen Group - A Multi-Specialty Psychiatry and Psychotherapy Practice

Disclosure: Nothing to disclose.

Thomas Cook, MD Resident Physician, Department of Psychiatry, University of Hawaii, John A Burns School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

David Bienenfeld, MD Professor, Departments of Psychiatry and Geriatric Medicine, Wright State University, Boonshoft School of Medicine

David Bienenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, Association for Academic Psychiatry

Disclosure: Nothing to disclose.

Acknowledgements

Carol Diane Berkowitz, MD Executive Vice Chair, Department of Pediatrics, Professor, Harbor-University of California at Los Angeles Medical Center

Carol Diane Berkowitz, MD is a member of the following medical societies: Alpha Omega Alpha, Ambulatory Pediatric Association, American Academy of Pediatrics, American College of Emergency Physicians, American Medical Association, American Pediatric Society, and North American Society for Pediatric and Adolescent Gynecology

Disclosure: Nothing to disclose.

O Joseph Bienvenu III, MD, PhD Assistant Professor, Department of Psychiatry, Johns Hopkins University School of Medicine

O Joseph Bienvenu III, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, and American Psychiatric Association

Disclosure: Nothing to disclose.

M Peter Chodynicki, MD Staff Physician, Department of Psychiatry, Johns Hopkins University School of Medicine

M Peter Chodynicki, MD is a member of the following medical societies: American Psychiatric Association

Disclosure: Nothing to disclose.

Dirk M Elston, MD Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Sing-Yi Feng, MD Assistant Professor, Department of Pediatrics, Division of Emergency Medicine, Section of Medical Toxicology, Univerity of Texas Southwestern Medical Center; Staff Toxicologist, North Texas Poison Center, Parkland Memorial Hospital

Sing-Yi Feng, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Medical Toxicology

Disclosure: Nothing to disclose.

Camila K Janniger, MD Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Camila K Janniger, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Jeffrey Meffert, MD Assistant Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, and Texas Dermatological Society

Disclosure: Nothing to disclose.

James J Nordlund, MD Professor Emeritus, Department of Dermatology, University of Cincinnati College of Medicine

James J Nordlund, MD is a member of the following medical societies: American Academy of Dermatology, Sigma Xi, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Caroly Pataki, MD Professor of Clinical Psychiatry and Behavioral Sciences, Department of Psychiatry, Division Chair, Child and Adolescent Psychiatry, Keck School of Medicine of the University of Southern California

Caroly Pataki, MD is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, New York Academy of Sciences, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Wanda M Patterson, MD Department of Dermatology, UMDNJ-New Jersey Medical School

Wanda M Patterson, MD is a member of the following medical societies: Sigma Xi

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, New York Academy of Medicine, and Sigma Xi

Disclosure: Nothing to disclose.

Jagvir Singh, MD Director, Division of Pediatric Emergency Medicine, Lutheran General Hospital of Park Ridge

Jagvir Singh, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Neziroglu F, Hsia C, Yaryura-Tobias JA. Behavioral, cognitive, and family therapy for obsessive-compulsive and related disorders. Psychiatr Clin North Am. 2000 Sep. 23(3):657-70. [Medline].

  2. Krebs G, Turner C, Heyman I, Mataix-Cols D. Cognitive behaviour therapy for adolescents with body dysmorphic disorder: a case series. Behav Cogn Psychother. 2012 Jul. 40(4):452-61. [Medline].

  3. Thomas I, Patterson WM, Szepietowski JC, Chodynicki MP, Janniger CK, Hendel PM, et al. Body dysmorphic disorder: more than meets the eye. Acta Dermatovenerol Croat. 2005. 13(1):50-3. [Medline].

  4. McElroy SL, Phillips KA, Keck PE Jr, Hudson JI, Pope HG Jr. Body dysmorphic disorder: does it have a psychotic subtype?. J Clin Psychiatry. 1993 Oct. 54(10):389-95. [Medline].

  5. Jakubietz M, Jakubietz RJ, Kloss DF, Gruenert JJ. Body dysmorphic disorder: diagnosis and approach. Plast Reconstr Surg. 2007 May. 119(6):1924-30. [Medline].

  6. Cotterill, JA, Millard, LG. Psychocutaneous disorders. Champion RH, Rook A, Ebling FJ, Wilkinson DS, eds. Rook/Wilkinson/Ebling Textbook of Dermatology. 6th ed. London, England: Blackwell Science; 1998. 2792-4.

  7. Phillips KA, McElroy SL. Insight, overvalued ideation, and delusional thinking in body dysmorphic disorder: theoretical and treatment implications. J Nerv Ment Dis. 1993 Nov. 181(11):699-702. [Medline].

  8. American Psychiatric Association. Obsessive-Compulsive and Related Disorders. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 5th ed. Arlington, Va: American Psychiatric Association; 2013.

  9. Phillips KA, Menard W, Fay C, Pagano ME. Psychosocial functioning and quality of life in body dysmorphic disorder. Compr Psychiatry. 2005 Jul-Aug. 46(4):254-60. [Medline]. [Full Text].

  10. Didie ER, Walters MM, Pinto A, Menard W, Eisen JL, Mancebo M, et al. A comparison of quality of life and psychosocial functioning in obsessive-compulsive disorder and body dysmorphic disorder. Ann Clin Psychiatry. 2007 Jul-Sep. 19(3):181-6. [Medline].

  11. Phillips KA, Diaz SF. Gender differences in body dysmorphic disorder. J Nerv Ment Dis. 1997 Sep. 185(9):570-7. [Medline].

  12. Phillips KA, Menard W, Fay C. Gender similarities and differences in 200 individuals with body dysmorphic disorder. Compr Psychiatry. 2006 Mar-Apr. 47(2):77-87. [Medline]. [Full Text].

  13. Phillips KA, Menard W. Suicidality in body dysmorphic disorder: a prospective study. Am J Psychiatry. 2006 Jul. 163(7):1280-2. [Medline]. [Full Text].

  14. Rief W, Buhlmann U, Wilhelm S, Borkenhagen A, Brähler E. The prevalence of body dysmorphic disorder: a population-based survey. Psychol Med. 2006 Jun. 36(6):877-85. [Medline].

  15. Koran LM, Abujaoude E, Large MD, Serpe RT. The prevalence of body dysmorphic disorder in the United States adult population. CNS Spectr. 2008 Apr. 13(4):316-22. [Medline].

  16. Haas CF. Champion A. Secor D. Motivating factors for seeking cosmetic surgery: a synthesis of the literature. Plastic Surgical Nursing. 2008 Oct-Dec. 28(4):177-82. [Medline].

  17. Phillips KA. Body dysmorphic disorder: the distress of imagined ugliness. Am J Psychiatry. 1991 Sep. 148(9):1138-49. [Medline].

  18. Allen A, Hollander E. Body dysmorphic disorder. Psychiatr Clin North Am. 2000 Sep. 23(3):617-28. [Medline].

  19. Cleveland WL, DeLaPaz RL, Fawwaz RA, Challop RS. High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period. Neural Plast. 2009. 2009:768398. [Medline].

  20. Feusner JD, Moody T, Hembacher E, Townsend J, McKinley M, Moller H. Abnormalities of visual processing and frontostriatal systems in body dysmorphic disorder. Arch Gen Psychiatry. 2010 Feb. 67(2):197-205. [Medline].

  21. Monzani B, Rijsdijk F, Anson M, Iervolino AC, Cherkas L, Spector T, et al. A twin study of body dysmorphic concerns. Psychol Med. 2012 Sep. 42(9):1949-55. [Medline].

  22. Feusner JD, Yaryura-Tobias J, Saxena S. The pathophysiology of body dysmorphic disorder. Body Image. 2008 Mar. 5(1):3-12. [Medline].

  23. Deckersbach T, Savage CR, Phillips KA. Characteristics of memory dysfunction in body dysmorphic disorder. J Int Neuropsychol Soc. 2000 Sep. 6(6):673-81. [Medline].

  24. Phillips KA, Atala KD, Albertini RS. Case study: body dysmorphic disorder in adolescents. J Am Acad Child Adolesc Psychiatry. 1995 Sep. 34(9):1216-20. [Medline].

  25. Didie ER, Kuniega-Pietrzak T, Phillips KA. Body image in patients with body dysmorphic disorder: evaluations of and investment in appearance, health/illness, and fitness. Body Image. 2010 Jan. 7(1):66-9. [Medline].

  26. Calogero RM, Park LE, Rahemtulla ZK, Williams KC. Predicting excessive body image concerns among British university students: the unique role of Appearance-based Rejection Sensitivity. Body Image. 2010 Jan. 7(1):78-81. [Medline].

  27. Buhlmann U, Teachman BA, Naumann E, Fehlinger T, Rief W. The meaning of beauty: implicit and explicit self-esteem and attractiveness beliefs in body dysmorphic disorder. J Anxiety Disord. 2009 Jun. 23(5):694-702. [Medline].

  28. Bienvenu OJ, Samuels JF, Riddle MA, Hoehn-Saric R, Liang KY, Cullen BA, et al. The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. Biol Psychiatry. 2000 Aug 15. 48(4):287-93. [Medline].

  29. Phillips KA, McElroy SL, Hudson JI, Pope HG Jr. Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both?. J Clin Psychiatry. 1995. 56 Suppl 4:41-51; discussion 52. [Medline].

  30. Stein DJ, Hollander E. Dermatology and conditions related to obsessive-compulsive disorder. J Am Acad Dermatol. 1992 Feb. 26(2 Pt 1):237-42. [Medline].

  31. Stein DJ, Hollander E. : APA Press. The spectrum of obsessive-compulsive related disorders. Hollander E, ed. Obsessive-Compulsive Related Disorders. Washington, DC: 1992. 241-71.

  32. Feusner JD, Arienzo D, Li W, Zhan L, Gadelkarim J, Thompson PM, et al. White matter microstructure in body dysmorphic disorder and its clinical correlates. Psychiatry Res. 2013 Feb 28. 211(2):132-40. [Medline]. [Full Text].

  33. Arienzo D, Leow A, Brown JA, Zhan L, Gadelkarim J, Hovav S, et al. Abnormal brain network organization in body dysmorphic disorder. Neuropsychopharmacology. 2013 May. 38(6):1130-9. [Medline]. [Full Text].

  34. Buhlmann U, Marques LM, Wilhelm S. Traumatic experiences in individuals with body dysmorphic disorder. J Nerv Ment Dis. 2012 Jan. 200(1):95-8. [Medline].

  35. Cotterill JA. Body dysmorphic disorder. Dermatol Clin. 1996 Jul. 14(3):457-63. [Medline].

  36. Mackley CL. Body dysmorphic disorder. Dermatol Surg. 2005 May. 31(5):553-8. [Medline].

  37. Phillips KA, Dufresne RG Jr, Wilkel CS, Vittorio CC. Rate of body dysmorphic disorder in dermatology patients. J Am Acad Dermatol. 2000 Mar. 42(3):436-41. [Medline].

  38. Sarwer DB, Wadden TA, Pertschuk MJ, Whitaker LA. Body image dissatisfaction and body dysmorphic disorder in 100 cosmetic surgery patients. Plast Reconstr Surg. 1998 May. 101(6):1644-9. [Medline].

  39. Alavi M, Kalafi Y, Dehbozorgi GR, Javadpour A. Body dysmorphic disorder and other psychiatric morbidity in aesthetic rhinoplasty candidates. J Plast Reconstr Aesthet Surg. 2011 Jun. 64(6):738-41. [Medline].

  40. Conrado LA, Hounie AG, Diniz JB, Fossaluza V, Torres AR, Miguel EC, et al. Body dysmorphic disorder among dermatologic patients: Prevalence and clinical features. J Am Acad Dermatol. 2010 Aug. 63(2):235-43. [Medline].

  41. Phillips KA, Kaye WH. The relationship of body dysmorphic disorder and eating disorders to obsessive-compulsive disorder. CNS Spectr. 2007 May. 12(5):347-58. [Medline].

  42. Phillips KA, Didie ER, Feusner J, Wilhelm S. Body dysmorphic disorder: treating an underrecognized disorder. Am J Psychiatry. 2008 Sep. 165(9):1111-8. [Medline]. [Full Text].

  43. Perugi G, Akiskal HS, Giannotti D, Frare F, Di Vaio S, Cassano GB. Gender-related differences in body dysmorphic disorder (dysmorphophobia). J Nerv Ment Dis. 1997 Sep. 185(9):578-82. [Medline].

  44. Grieve FG. A conceptual model of factors contributing to the development of muscle dysmorphia. Eat Disord. 2007 Jan-Feb. 15(1):63-80. [Medline].

  45. Bjornsson AS, Dyck I, Moitra E, Stout RL, Weisberg RB, Keller MB, et al. The clinical course of body dysmorphic disorder in the Harvard/Brown Anxiety Research Project (HARP). J Nerv Ment Dis. 2011 Jan. 199(1):55-7. [Medline]. [Full Text].

  46. Veale D, Boocock A, Gournay K, Dryden W, Shah F, Willson R, et al. Body dysmorphic disorder. A survey of fifty cases. Br J Psychiatry. 1996 Aug. 169(2):196-201. [Medline].

  47. Cotterill JA, Cunliffe WJ. Suicide in dermatological patients. Br J Dermatol. 1997 Aug. 137(2):246-50. [Medline].

  48. Phillips KA, Quinn G, Stout RL. Functional impairment in body dysmorphic disorder: a prospective, follow-up study. J Psychiatr Res. 2008 Jul. 42(9):701-7. [Medline]. [Full Text].

  49. Rabe-Jablonska J. [Results of long-term observation (3-11 years) of patients with dual diagnosis: body dysmorphic disorder and delusional disorder, somatic type]. Psychiatr Pol. 1998 Mar-Apr. 32(2):143-53. [Medline].

  50. Dingemans AE, van Rood YR, de Groot I, van Furth EF. Body dysmorphic disorder in patients with an eating disorder: prevalence and characteristics. Int J Eat Disord. 2012 May. 45(4):562-9. [Medline].

  51. Phillips KA, Pagano ME, Menard W, Stout RL. A 12-month follow-up study of the course of body dysmorphic disorder. Am J Psychiatry. 2006 May. 163(5):907-12. [Medline]. [Full Text].

  52. Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull. 1997. 33(1):17-22. [Medline].

  53. Butler Hospital. Butler Hospital Screening Questionnaire for Adolescents: Do I have BDD. Butler Hospital. Available at http://www.butler.org/body.cfm?id=237. Accessed: 6.6.10.

  54. Veale D, Eshkevari E, Ellison N, Cardozo L, Robinson D, Kavouni A. Validation of genital appearance satisfaction scale and the cosmetic procedure screening scale for women seeking labiaplasty. J Psychosom Obstet Gynaecol. 2013 Mar. 34(1):46-52. [Medline].

  55. Hunter-Yates J, Dufresne RG Jr, Phillips KA. Tanning in body dysmorphic disorder. J Am Acad Dermatol. 2007 May. 56(5 Suppl):S107-9. [Medline].

  56. Phillips KA, Taub SL. Skin picking as a symptom of body dysmorphic disorder. Psychopharmacol Bull. 1995. 31(2):279-88. [Medline].

  57. Yutzy, SParish, B. Somatoform Disorders. Tasman, A, Kay, J, Lieberman, J, First, M, Maj, M. Psychiatry. Third. London: John Wiley & Sons; 2008. 2: 1538-1542/74.

  58. Nakata AC, Diniz JB, Torres AR, de Mathis MA, Fossaluza V, Bragancas CA, et al. Level of insight and clinical features of obsessive-compulsive disorder with and without body dysmorphic disorder. CNS Spectr. 2007 Apr. 12(4):295-303. [Medline].

  59. Conroy M, Menard W, Fleming-Ives K, Modha P, Cerullo H, Phillips KA. Prevalence and clinical characteristics of body dysmorphic disorder in an adult inpatient setting. Gen Hosp Psychiatry. 2008 Jan-Feb. 30(1):67-72. [Medline]. [Full Text].

  60. Phillips KA, Kelly MM. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder. Int Clin Psychopharmacol. 2009 Jan. 24(1):26-8. [Medline]. [Full Text].

  61. Picavet V, Gabriëls L, Jorissen M, Hellings PW. Screening tools for body dysmorphic disorder in a cosmetic surgery setting. Laryngoscope. 2011 Dec. 121(12):2535-41. [Medline].

  62. Wilhelm S, Greenberg JL, Rosenfield E, Kasarskis I, Blashill AJ. The Body Dysmorphic Disorder Symptom Scale: Development and preliminary validation of a self-report scale of symptom specific dysfunction. Body Image. 2016 Mar 10. 17:82-87. [Medline].

  63. Ipser JC, Sander C, Stein DJ. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst Rev. 2009 Jan 21. CD005332. [Medline].

  64. Ravindran AV, da Silva TL, Ravindran LN, Richter MA, Rector NA. Obsessive-compulsive spectrum disorders: a review of the evidence-based treatments. Can J Psychiatry. 2009 May. 54(5):331-43. [Medline].

  65. [Guideline] British Psychological Society, Royal College of Psychiatrists. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. National Guideline Clearinghouse. 2006;. Available at http://guideline.gov/summary/summary.aspx?doc_id=9369.

  66. Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image. 2008 Mar. 5(1):13-27. [Medline]. [Full Text].

  67. Sondheimer A. Clomipramine treatment of delusional disorder-somatic type. J Am Acad Child Adolesc Psychiatry. 1988 Mar. 27(2):188-92. [Medline].

  68. Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999 Nov. 56(11):1033-9. [Medline].

  69. Krasowska D, Szymanek M, Schwartz RA, Myslinski W. Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors. J Am Acad Dermatol. 2007 May. 56(5):848-53. [Medline].

  70. Phillips KA. Body dysmorphic disorder: clinical aspects and treatment strategies. Bull Menninger Clin. 1998 Fall. 62(4 Suppl A):A33-48. [Medline].

  71. Allen A, Hadley SJ, Kaplan A, Simeon D, Friedberg J, Priday L, et al. An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr. 2008 Feb. 13(2):138-44. [Medline].

  72. [Guideline] National Collaborating Centre for Mental Health. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. London (UK): British Psychological Society, Royal College of Psychiatrists; 2006. 350 p. (National clinical practice guideline; no. 31).

  73. Greenberg JL, Mothi SS, Wilhelm S. Cognitive-Behavioral Therapy for Adolescent Body Dysmorphic Disorder: A Pilot Study. Behav Ther. 2016 Mar. 47 (2):213-24. [Medline].

  74. Crerand CE, Infield AL, Sarwer DB. Psychological considerations in cosmetic breast augmentation. Plast Surg Nurs. 2007 Jul-Sep. 27(3):146-54. [Medline].

  75. Polo M. Body dysmorphic disorder: a screening guide for orthodontists. Am J Orthod Dentofacial Orthop. 2011 Feb. 139(2):170-3. [Medline].

  76. Sheppard NP, O'Loughlin S, Malone JP. Psychogenic skin disease: a review of 35 cases. Br J Psychiatry. 1986 Nov. 149:636-43. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.